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Summary 
Recombinant apolipoprotein E-3 (ApoE-3), expressed in Escherichia coli, was purified and used 
in an in vitro and an in vivo model system for acquired immunodeficiency syndrome-associated 
Kaposi's sarcoma (AIDS-KS). This protein blocked cell proliferation and chemotaxis of AIDS-KS 
cells in response to activated lymphocyte conditioned medium (AL-CM) and oncostatin M (OSM). 
ApoE-3 also inhibited the formation of neoangiogenic lesions induced in BALB/c nu/nu  mice 
by AIDS-KS cells. These findings represent a novel and potentially less toxic therapeutic approach 
for the treatment  of AIDS-KS. 
W 
e previously developed an in vitro and an in vivo model 
system (1,  2)  to  study the  pathogenesis  of AIDS- 
associated Kaposi's sarcoma (AIDS-KS) (3-7). Recently, we 
reported on a novel approach for the treatment of AIDS-KS 
using a bacteria-derived sulfated polysaccharide-peptidoglycan 
termed DS-4152 (8-11). This observation stimulated our in- 
terest in understanding  the role of other sulfated glycans in- 
cluding heparin/heparan  sulfate proteoglycans (HSPG) (12), 
and the molecules that interact with HSPG in the regulation 
of AIDS-KS cell growth, chemotaxis, and neoangiogenesis. 
Several plasma proteins including platelet factor 4 (D), os- 
teonectin/secreted protein acidic and rich in cysteine (14), and 
thrombospondin  (15-17) have antiangiogenic  properties in 
vitro and in vivo. Platelet factor 4 (13) and thrombospondin 
(15-17) have antiangiogenic properties in vitro and in vivo, 
and are strong heparin-binding proteins as well. Another pro- 
tein that is ubiquitously expressed and has strong affinity for 
heparin and HSPG is Apolipoprotein E (ApoE) (18). Recently, 
we demonstrated that recombinant ApoE-3 (19) specifically 
inhibited the in vitro proliferation of bovine endothelial and 
human smooth muscle cells, as well as several human tumor 
cell lines (20). Through receptor binding studies we demon- 
strated that ApoE-3 competed with basic fibroblast growth 
factor for binding to the low affinity fibroblast growth factor 
receptor (20). 
In  the  present  report  we investigated  further  whether 
ApoE-3 could function as an antiangiogenic molecule in our 
in vitro and in vivo AIDS-KS model system. The findings 
presented suggest a novel and potentially less toxic therapeutic 
approach for the treatment  of AIDS-KS (3, 4,  6,  7,  21). 
Materials  and Methods 
Reagents.  Human recombinant ApoE-3 isoform was expressed 
in Escherichia coli and purified as previously described (19). Purified 
recombinant human ApoE-3 was first lyophilized from a solution 
of I mg of ApoE-3/ml containing 2 mM sodium bicarbonate and 
I mM cysteine. The lyophilized ApoE-3 was stored at - 70~  under 
these conditions the recombinant ApoE-3 is stable for years. ApoE-3 
was reconstituted in sterile distilled water at concentrations of 1-10 
mg/ml. To this solution,  10% (vol/vol) of 10x  Dulbecco's PBS 
(D-PBS) (GIBCO BRL, Gaithersburg, MD) was added. The ApoE-3 
solutions were used immediately, or stored in small aliquots at 
-20~  and used within 2-3 wk. Activated lymphocyte conditioned 
media (AL-CM) was prepared from PHA-activated PBMC. Periph- 
eral blood was obtained from normal volunteers at the National 
Institutes of Health Blood Bank. PBMC were isolated using lym- 
phocyte separation medium  (Organon  Teknika Corp.,  Durham, 
NC). This medium allows the separation of granulocytes and red 
blood cells from the mononuclear cells, e.g., lymphocytes, mono- 
cytes, dendritic cells, etc., by density centrifugation. Isolated PBMC 
were cultured in R.PMI 1640 (GIBCO BRL) containing 10% FCS 
(GIBCO BRL) and 2/zg/ml of Bacto-phytohemagglutinin-P (Difco 
Laboratories, Detroit, MI), 2  x  106 cells/ml in ILPMI 1640 con- 
taining  10% FCS and 20 U/ml of IL-2 (Boehringer  Mannheim 
Corp.,  Indianapolis, IN). After 72 h, the AL-CM was collected, 
filtered through a 0.45-micron filter (Coming Glass Co., Coming, 
NY), aliquoted, and stored at  -20~  AL-CM that stimulated a 
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these studies. Oncostatin  M (OSM) (22) levels were determined 
in the AL-CM using the OSM Quantikine  Immunoassay kit (IL 
& D Systems, Minneapolis, MN). The AL-CM prepared as above 
contained 20-40 pg/ml of OSM (22). Recombinant human OSM 
(22) was obtained from PeproTech (Minneapolis, MN). 
Cells.  AIDS-KS cells were isolated and cultured as previously 
described (1). The AIDS-KS cell strain RW248 was isolated from 
the pleural effusion of a patient  with  AIDS-KS. The RW248 
AIDS-KS cell strain has a normal karyotype, and the cell pheno- 
type and growth characteristics in vitro and in vivo are similar to 
the other AIDS-KS cell strains previously described (1, 2). 
Thymidine Incorporation into DNA.  DNA synthesis was deter- 
mined  as  follows: the  KS cell strain,  tLW248,  was  grown to 
confluence, at which time the medium  was replaced with fresh 
RPMI 1640 (GIBCO BRL) containing 0.5% FCS (GIBCO BILL) 
and cultured  for 72 h to growth-arrest  the cells. The cells were 
trypsinized,  plated at a density of 2  x  104 cells/well in 24-well 
tissue culture plates (Becton Dickinson & Co., Lincoln Park, NJ), 
and cultured  in KPMI 1640, 1% FCS with either 20% AL-CM 
medium or OSM (22) 30 ng/ml, and increasing concentrations of 
native ApoE-3 (19). Each concentration of ApoE-3 was assayed in 
triplicate.  After 24 h,  the cells were pulsed with  1 #Ci/ml of 
[methyl-3H]thymidine  (New England  Nuclear  [NEN], Boston, 
MA) (1 Ci  =  37 GBq) for 12 h. After 12 h triplicate wells were 
washed twice with cold PBS, fixed at room temperature with I ml 
of methanol/acetic acid (3:1) for 1 h, washed twice with 80% eth- 
anol, and allowed to air dry. To each well, 300 #1 of 0.25% trypsin 
(GIBCO BILL)  wash was added and incubated at 37~  for 30 min, 
and then 100/zl of 10% sodium dodecyl sulfate was added and 
the contents in each well were dissolved  in 10 ml of  Aquasol (NEN) 
for scintillation counting. 
CelIProliferation Assay.  For cell proliferation assays nongrowth- 
arrested cells, 104 cells/well were seeded in triplicate in 96-well flat 
bottomed plates (Becton Dickinson & Co.) that contained the re- 
quired dilutions of native ApoE-3 (19), heat inactivated ApoE-3 
(19), or buffer in ILPMI 1640 containing  1% FCS. After 3 d the 
cell density was determined using the protocol outlined in the cell 
proliferation assay kit (Promega Corp., Madison, WI). This assay 
is based on the cellular conversion of tetrazolum  salt into a blue 
formazan product that can then be detected by measuring absor- 
bance at 570 nm. 
Cell Migration Assay.  Chemotaxis of the R.W248 AIDS-KS  cells 
was performed in a modified Boyden chamber assay. 8-micron pore 
polyvinlypyrrolidine-free nucleopore polycarbonate filters (Neuro 
Probe, Inc., Cabin John, MD) were coated with gelatin (0.1 mg/ml 
in 0.1% acetic acid). Subconfluent AIDS-KS cells, ILW248, were 
harvested the first day after passage by brief treatment with 0.05% 
trypsin  and 0.02% EDTA. The cells were reequilibrated for 2 h 
at room temperature in KPMI 1640 containing 10% FCS (Biofluids, 
ILockville, MD) and 20% AL-CM. Chemoattractants  OSM (22) 
or AL-CM and cells at 0.5  x  106 cells/ml were resuspended in 
RPMI 1640 containing 0.1% BSA (Sigma Chemical Co., St. Louis, 
MO). 28 #1 of each chemoattractant  were loaded into the lower 
chamber wells. 56 #1 of cells + ApoE-3 (19) (at the indicated con- 
centrations)  were loaded in the upper chamber wells. Migration 
was performed at 37~  for 3.5 h. The filters were fixed, stained, 
and quantified microscopically by counting cells in three separate 
areas of each stained well. The nonstimulated migration determined 
at each ApoE-3 (19) concentration was subtracted from stimulated 
motility and is expressed as percentage of the respective controls. 
The values are mean of triplicate determinations and the bars indi- 
cate standard deviations, n  =  3. 
Angiogenesis In Viw  2  x  106 AIDS-KS cells, RW248 passage 
6-8, were transplanted subcutaneously on day 0 on the backs of 
male BALB/c nu/nu athymic mice. The mice were administered 
PBS, ApoE-3 (19) 0.2 mg, ApoE-3 (19) 0.4 mg, or ApoE-3 (19) 
0.8 mg i.v. on days 0-4. On day 6 the animals were killed, and 
the KS-like lesions were measured along with other macroscopic 
characteristics. The values are representative of four in vivo experi- 
ments representing the mean and the error bars of the standard 
deviations. Statistical analysis was performed using the two-tailed 
Student's  t test. 
Results and Discussion 
Inhibition of DNA Synthesis and Cell Proliferation by ApoE-3. 
In a dose-dependent manner, both ceU proliferation (Fig.  1 
A) and DNA synthesis (Fig. 1, B and C) were inhibited when 
ApoE-3 (19) was added to growth media containing either 
AL-CM (Fig.  1 B) or OSM (22)  (Fig.  1, A  and C).  OSM 
(22) a cytokine secreted into the conditioned medium of ac- 
tivated lymphocytes, is a member of the neuropoietic cytokine 
family and one of the most effective exogenous growth factors 
for the AIDS-KS cells (23-25).  This inhibitory effect was 
abolished if the ApoE-3 (19) was heat inactivated, suggesting 
that the inhibitory effect requires the native conformation 
of ApoE-3 (Fig.  1 A). ApoE-3 (19) blocked the release from 
growth arrest when AL-CM (Fig.  1 B) or OSM (Fig.  1 C) 
were added to growth arrested AIDS-KS cells. Release from 
growth arrest is required to recruit new endothelial cells for 
angiogenesis (26, 27). The concentrations of ApoE-3, required 
to inhibit DNA synthesis by 50% after growth arrest, were 
0.07 #M in  the presence of 20%  AL-CM (Fig.  1 B), and 
0.7/zM in the presence of recombinant OSM (22), 50 ng/ml 
(Fig.  1 C).  The stronger inhibitory activity of ApoE-3 in 
the presence of AL-CM may result from the much lower levels 
of OSM in AL-CM than the exogenous OSM used in these 
experiments. These data suggest that ApoE-3 is a potential 
antiangiogenic molecule that functions by inhibiting growth- 
arrested cells e.g., vascular endothelium or the AIDS-KS cells 
from responding to growth factors.  In addition, ApoE-3 in- 
hibits AIDS-KS cell proliferation even if cells are not growth 
arrested by serum starvation (Fig. 1 A), suggesting more than 
one mechanism of action. 
Inhibition of Migration  by ApoE-3.  Migratory properties 
of the AIDS-KS cells (1) were also inhibited by ApoE-3 (Fig. 
2). Migration of endothelial cells in response to chemotactic 
stimuli is a key aspect of angiogenesis.  Previous work (28-30) 
in our laboratory demonstrated that AL-CM contains a number 
of growth factors that may influence angiogenesis including 
IL-1,  IL-6,  TNF-ot,  and  OSM  that  may also  function as 
chemoattractants for the AIDS-KS cells. These factors in vivo 
could contribute to the invasiveness  and multifocal lesions 
characteristic of the AIDS-KS lesions found in patients. 
The migration of the AIDS-KS cells (1) to the chemoat- 
tractants AL-CM and OSM (22) was tested using a modified 
Boyden chamber assay. AL-CM and OSM stimulated by two- 
to threefold the migration of AIDS-KS cells from the upper 
chamber to the lower chamber. The optimal concentration 
of AL-CM and OSM that stimulated cell migration also max- 
imally stimulated the growth of the AIDS-KS cells. ApoE-3 
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Figure 1.  Assays  for DNA synthesis and cell proliferation of the AIDS-KS cells in the presence of ApoE-3 and growth factors. For cell proliferation 
assays (A) nongrowth-arrested  cells, 104 cells/well were seeded in triplicate in 96-well fiat-bottomed plates (Falcon Labware, Franklin Lakes, NJ) that 
contained the required dilutions of native ApoE-3 (0), heat-inactivated ApoE-3 (t), or buffer (m) in RPMI 1640 containing 1% FCS. After 3 d the 
cell density was determined using the protocol outlined in the call proliferation assay kit (Promega Corp.,  Madison, WI). This assay is based on the 
cellular conversion of tetrazolum salt into a blue formazan product  that is detected by measuring absorbance at 570 nm. DNA synthesis (B) and (C) 
was determined  as follows: the KS cell strain,  RW248 was grown to confluence, at which time the medium was replaced with fresh RPMI 1640 
(GIBCO BRL) containing 0.5% FCS (GIBCO BILL) and cultured for 72 h to growth-arrest  the cells. The cells were trypsinized, plated at a density 
Of 2  X 104 cells/well in 24-well tissue culture plates (Falcon Labware), and cultured in RPMI 1640, 1% FCS, with either 20% AL-CM medium (m) 
(12) (B) or OSM 30 ng/ml (A) (PreproTech) (C), and increasing concentrations of native ApoE-3. Each concentration  of ApoE-3 was assayed  in triplicate. 
After 24 h the cells were pulsed with 1 #Ci/ml of [methyl-3H]thymidine (NEN) (1 Ci =  37 GBq) for 12 h. After 12 h, triplicate wells were washed 
twice with cold PBS, fixed at room temperature with 1 ml of methanol/acetic  acid (3:1) for 1 h, washed twice with 80% ethanol,  and allowed to 
air dry. To each well 300 #I of 0.25% trypsin (GIBCO BILL) wash was added and incubated at 37~  for 30 min, then 100 #I of 10% sodium dodecyl 
sulfate was added and the contents in each well was dissolved in 10 ml of Aquasol (NEN) for scintillation counting. The results shown are representative 
of three experiments at different cell passsages. In all three panels the values  are the mean of triplicate determinations, and the bars  indicate standard deviations. 
over the concentration range of  0.8-1.6/xM inhibited AL-CM 
and OSM stimulated  migration of AIDS-KS cells. As dis- 
cussed above regarding cell proliferation,  the concentration 
of OSM in AL-CM is not high enough to account for the 
stimulation in cell growth and migration. The inhibitory effect 
on cell migration of ApoE-3 in the presence of AL-CM is 
likely due to competition with other chemotactic factors in 
AL-CM (28-30). 
Inhibition of Angiogenesis In Vivo.  The in vitro results led 
us to ask whether ApoE-3 had antiangiogenic properties in 
vivo. AIDS-KS cells were subcutaneously  injected into athymic 
nude mice and ApoE-3 was administered intravenously. In 
these experiments (Fig. 3) ApoE-3 treatment produced a dose- 
dependent decrease in the size of the angiogenic KS-like le- 
sions induced by subcutaneously injected AIDS-KS cells. The 
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KS-like lesions in mice treated with 0.8 mg or 0.4 mg ApoE-3 
were significantly smaller than the lesions of PBS-treated con- 
trol mice,/~ <0.000008 andp  =  0.0008, respectively. Grossly, 
the lesions observed in mice treated with 0.8 or 0.4 mg of 
ApoE-3  (19)  were pale in appearance compared  to the ery- 
thematous lesions in the PBS  and 0.2  mg ApoE-3-treated 
mice.  The typical lesion observed  histologically in the ab- 
sence of ApoE-3 was characterized by spindle cells (primarily 
Figure 2.  The effect of ApoE-3 on chemotaxis of AIDS-KS cells to 
OSM or AL-CM. Chemotaxis  of the RW248 AIDS-KS cells was per- 
formed in a modified Boyden chamber assay. 8-#M pore polyvinlypyrro- 
lidine-free  nucleopore polycarbonate filters (Neuro Probe, Inc.) were coated 
with gelatin (0.1 mg/ml in 0.1% acetic acid). Subconfluent AIDS-KS cells 
were harvested on the first day after passage by brief treatment with 0.05% 
trypsin and 0.02% EDTA. The cells were reequilibrated for 2 h at room 
temperature in ILPM11640 containing  10% FCS (Biofluids) and 20% AL- 
CM. Chemoattractants  (OSM or AL-CM) and cells at 0.5  x  106 cells/ml 
were resuspended in RPMI 1640 containing  0.1% BSA (Sigma Chemical 
Co.). 28 #1 of each chemoattractant  was loaded into the lower chamber 
wells. 56/zl of cells + ApoE-3 (at the indicated concentrations) were loaded 
in the upper chamber wells. Migration was performed at 37~  for 3.5 h. 
The filters were fixed, stained, and quantified microscopically by counting 
cells in three separate areas of each stained well. The data presented are 
from one representative experiment which was repeated at least three times 
with three different passages of cells. The number of cells migrating to 
OSM (m) at 25 ng/ml (140 +  14) or 20% AL-CM ([3) (168 _+ 10) minus 
basal motility (59.5 _+ 8) in the absence of inhibitor are defined as 100% 
of control. The nonstimulated  migration determined at each ApoE-3 con- 
centration was subtracted from stimulated motility and is expressed as per- 
centage of the respective controls. The values are the mean of triplicate 
determinations  and the bars indicate standard deviations. 
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Figure 3.  Intravenous  ApoE-3 
inhibits the formation  of angio- 
genic  lesions  induced  by AIDS-KS 
cells  inoculated  into athymic  nude 
mice. 2  x  106 AIDS-KS cells, 
RW248 passage 6-8, were trans- 
planted subcutaneously  on day 0 
in  the backs of male BALB/c 
nu/nu athymic mice. The mice 
were  administered PBS  (I), 
ApoE-3 0.2 mg ([]), ApoE-3 0.4 
mg (Fq), or ApoE-3 0.8 mg (D) 
on days 0-4 (B). On day 6 the 
animals were killed, and  the 
tumor size was measured along 
with other  macroscopic  character- 
istics of the tumors. The values 
are representative  of four in vivo 
experiments representing  the mean and the error bars show  the standard 
deviations.  Statistical  analysis  was performed  using  the two-tailed  Student's 
t test. *ApoE-treated  mice at 0.4 mg vs. PBS-treated  mice,  p = 0.0008. 
*ApoE-treated mice at 0.8 mg vs. PBS-treated mice,  p <0.000008. 
of murine origin), inflammatory cells, and neoangiogenesis 
(Fig. 4 A). In contrast, the ApoE-3-treated mice had either 
no lesions at the highest doses, or lesions  devoid of spindle 
and inflammatory cells,  and neoangiogenesis (Fig.  4 B). 
In these experiments, ApoE-3 strongly inhibited prolifer- 
ation and migration of the AIDS-KS cells, as well as the de- 
velopment of KS-like lesions in nude mice.  These in vitro 
and in vivo results suggest a possible role for ApoE-3 in the 
regulation of AIDS-KS. 
The most studied functions of ApoE include its role in 
cholesterol metabolism. ApoE is a polymorphic protein con- 
sisting of three isoforms, ApoE-2, E-3, and E-4 (18). These 
isoforms are the products of three alleles at a single gene locus. 
The normal allele, found in 60%  of individuals, produces 
ApoE-3, whereas two mutant alleles result in the synthesis 
of ApoE-3 and E-4. These ApoE isoforms have varied effects 
on cholesterol metabolism. ApoE-3 is found in high density 
lipoproteins (HDL) and very low density lipoproteins (LDL) 
and mediates high aflanity  binding to the LDL receptor (18). 
Decreased levels of ApoE-3 are associated with an increased 
risk of atherosclerosis. ApoE-2 and E-4 bind the LDL receptor 
poorly, therefore individuals that express these isoforms have 
an increased  risk of atherosclerosis.  However, ApoE is syn- 
thesized by a number of cells that have no known role in 
cholesterol homeostasis, suggesting that ApoE may have other 
cellular functions depending upon the ApoE isoform expressed 
(18). For example, the expression of ApoE-4 is also associated 
with the development of  late onset Alzheimer's disease  (31, 32). 
AIDS-KS (3-7) is a cytokine-mediated disease  where inflam- 
matory cytokines e.g., IL-1, IL-6, TNF-ot, OSM, and HIV-1 
Tat proteins may cooperate in its induction and progression 
(28-30). Atherosclerosis (33, 34) is also a cytokine-mediated 
disease that is characterized by activated immune cells, smooth 
muscle hyperplasia,  and altered cholesterol metabolism (33, 
34). Activated lymphocytes and macrophages produce cyto- 
kines, including OSM, that stimulate the growth of intimal 
smooth muscle cells (35). OSM may therefore play a role in 
the pathogenesis of atherosclerosis (35), in addition to its role 
in the pathogenesis of  AIDS-KS. We demonstrated in previous 
studies (20) that ApoE-3 inhibits smooth muscle prolifera- 
tion in vitro. The ability of ApoE-3 to inhibit the prolifera- 
tion and migration of AIDS-KS cells in vitro, as well as the 
inhibition of the development of KS-like lesions in nude mice 
suggest  that  ApoE-3  may function as  a  key regulator in 
AIDS-KS. 
What are the ApoE levels in HIV-l-infected patients with 
KS as compared with other HIV-l-infected patients and age- 
matched controls? These ApoE levels have not been measured 
to date. However, the lipid abnormalities described in HIV- 
1-infected patients include increased triglycerides,  decreased 
plasma LDL and HDL which constitutes an LDL B pheno- 
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Figure 4.  Histology  of  angiogenic  lesions  in- 
duced by KS cell strain RW248 in the absence 
of  ApoE-3 (.4) and presence  ofApoE-3  (B). Male 
BALB/c nu/nu mice received (A) daily  intrave- 
nous injections of normal saline and with (B) 
daily  intravenous  injections  of  0.4 mg/mouse  of 
ApoE-3. The in vivo  experiments  were  performed 
as described  in Fig. 3. On day 6 the angiogenic 
lesions were observed, measured, fixed  in 10% 
formalin, paraffin  embedded, cut, and stained 
with hematc0oflin  & eosin. The histology  shown 
is from one representative  experiment.  Bar, 100 
microns. 
Treatment of AIDS-associated  Kaposi's Sarcoma Using Apolipoprotein E type (36). Persons with the LDL B phenotype have threefold 
increased risk of myocardial infarction when they acquire this 
atherogenic lipid profile (37). The LDL B phenotype is in- 
creased 2.5-fold in HIV-l-infected patients as compared with 
age matched controls (36) and is a result of HIV-1 infection 
causing an increase in serum IFN-ot levels (38,  39).  Plasma 
HDL levels decrease early in the clinical course of HIV-l-in- 
fected patients, before they develop  clinical  signs of AIDS 
(38).  Since most of these studies  arise from centers where 
the HIV-1-infected patients are primarily homosexual or bi- 
sexual males,  we do not know if these lipid abnormalities 
are similar in all groups of HIV-l-infected patients. Our data 
suggests that a closer analysis of plasma ApoE protein iso- 
form levels and other plasma lipid levels in patients with and 
without KS should be performed. 
Effective treatments for AIDS-KS (3-7) include low dose 
combinations of doxorubicin, bleomycin, and vincristine or 
IFN-o~ (40-42). Most HIV-l-infected patients with KS are 
unable to tolerate aggressive chemotherapy due to hemato- 
logic and immunologic complications secondary to HIV-1 
infection (40-42).  As a result, it is very important that we 
develop effective therapies  for AIDS-KS (3-7) that will not 
have the same  spectrum  of systemic  toxicities as standard 
chemotherapeutic approaches  (40-42). 
In studies where 10 mg of nonrecombinant ApoE was ad- 
ministered intravenously three times per week to Watanabe 
rabbits over an 8.5-mo period there was no deterioration of 
kidney and liver functions or peripheral blood counts (43), 
although the size of the atherosclerotic plaques  was signi- 
ficantly reduced. Pharmocokinetic studies (data not shown) 
of ApoE-3 in BALB/c nu/nu mice demonstrate that the half- 
life of ApoE-3 was 84 min. The liver and plasma had nearly 
identical peak concentrations of ApoE-3 due to rapid receptor- 
mediated uptake into the liver. ApoE-3 did not accumulate 
in other organs or fluids e.g., kidney or bile. This likely ex- 
plains the lack of systemic toxicity of  ApoE-3 in the Watanabe 
rabbits. In the in vivo KS model, where there is a blood supply 
developing from preexisting vessels, we would expect an ac- 
cumulation of ApoE at this site. Based on the results presented 
above, we think that ApoE-3 (19) has potential as a novel 
therapeutic agent for the treatment of AIDS-KS. 
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